ASCO 2026 Plenary: RASolute-302

About this episode

This episode discusses the RASolute 302 trial presented at the 2026 ASCO Plenary, highlighting its significant findings on daraxonrasib's effectiveness in treating mPDAC.

This week’s episode will be focusing on the 2026 ASCO Plenary that received a standing ovation, the RASolute 302 trial. The RASolute 302 trial is a landmark phase 3 study demonstrating that daraxonrasib doubled overall survival compared to chemotherapy in previously treated (2L) metastatic pancreatic ductal adenocarcinoma (mPDAC).

People in this episode

Hosts: Sam, Karine

Topics covered

• ASCO Plenary
• RASolute 302 trial
• daraxonrasib
• metastatic pancreatic ductal adenocarcinoma
• overall survival
• phase 3 study

Keywords

• ASCO 2026
• RASolute 302
• daraxonrasib
• overall survival
• mPDAC
• phase 3 study

Mentioned in this episode

Organizations: RASolute 302 trial

Products: daraxonrasib

Books & works: RASolute-302

Places: metastatic pancreatic ductal adenocarcinoma

More episodes of Two Onc Docs

• ASCO Annual Meeting 2026 Preview · May 25, 2026 · 11 min
• Von Willebrand Disease (VWD) 2026 UPDATE · May 18, 2026 · 13 min
• Aplastic Anemia 2026 UPDATE · May 11, 2026 · 12 min
• Metastatic Bladder Cancer 2026 UPDATE · May 4, 2026 · 9 min
• Localized Bladder Cancer 2026 UPDATE · April 27, 2026 · 13 min
• 4 Years with Two Onc Docs · April 20, 2026 · 12 min